Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study

"Rituximab 375 mg/m² intravenously on Day 0 of each 21-day cycle~High-dose Methotrexate (HD-MTX) 3.5 g/m² intravenously over 4 hours on Day 1 of each cycle~Selinexor 80 mg orally once weekly (on Days 1, 8, and 15) during each cycle~Treatment is administered every 21 days for up to 6 cycles. Tumor response will be evaluated every 3 cycles.~Patients who achieve a partial response (PR) or better will undergo consolidative low-dose whole-brain radiotherapy (WBRT) at 23.4 Gy in 13 fractions."